SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

ALNY

ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed3d 10h ago SEC0001422848-26-000134
Passive stake amendment
Actionable Insight • Neutral

Monitor for any further reductions by CRGI or other large passive holders. The decrease is modest and consistent with routine rebalancing; no immediate read-through for the stock.

DirectionNeutral
Confidencehigh
Horizonweeks
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Capital Research Global Investors (CRGI) filed an amended Schedule 13G disclosing a 8.2% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, down from 10.4% in the prior filing. The reduction reflects routine portfolio rebalancing by a large passive holder and does not signal any change in investment intent or control.

Key Financial Metrics

Stake
8.2%
Investor
Capital Research Global Investors
Investor Type
mutual fund

Key Facts

  • CRGI disclosed beneficial ownership of 10,940,905 shares of Alnylam common stock as of September 30, 2026.
  • The stake represents 8.2% of the 133,809,118 shares outstanding.
  • This is a decrease from the prior filing where CRGI reported a 10.4% stake.
  • The filing certifies passive intent with no plans to influence control.
  • CRGI is a division of Capital Research and Management Company and its affiliates.

Financial Impact

CRGI reduced its stake from 10.4% to 8.2%, a decrease of approximately 2.2 percentage points or roughly 2.9 million shares based on outstanding shares.

ownership percentage

Risk Factors

  • Further selling by CRGI or other large holders could pressure the stock.
  • No indication of activist intent; passive filing status unchanged.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001422848-26-000134
Document: 0001422848-26-000134-index.html0001422848-26-000134
Document: 0001422848-26-000134.txt0001422848-26-000134

Track record

15 reports on ALNY

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $165.50 Now $159.73 −3.49% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  4. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  5. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  6. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  7. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
  9. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
  10. Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026